PMOS/PCOS and Insulin Resistance: Symptoms, Diet, and Treatment

If your fasting blood sugar came back "perfectly normal" but you are still gaining weight around your midsection, crashing after lunch, fighting jawline acne, and watching your cycles drift further apart — you are not imagining the disconnect. You are likely sitting at the early stage of insulin resistance, the metabolic engine behind roughly 70 percent of PCOS cases.

Polycystic ovary syndrome (PCOS) — also called PMOS in recent medical literature after a 2026 global consensus formally renamed the condition to polyendocrine metabolic ovarian syndrome (Teede et al. 2026) — is the condition you may have been diagnosed with. The insulin-resistant pattern is the single clearest argument for the rename: this version of the disease starts in your pancreas and your liver, not your ovaries. By the time you see the irregular cycles, the acne, and the weight pattern, the metabolic loop has been running for years.

Insulin resistance starts long before your blood sugar ever looks abnormal on a standard test. Your muscle and fat cells stop responding to insulin, so your pancreas simply makes more of it to compensate. For a while this works — but the cost is steadily rising insulin levels, and that high circulating insulin is what drives most of the PCOS symptoms you are feeling. Here is how the loop works, how to identify it from your bloodwork, and what changes the trajectory.

What is the link between PMOS/PCOS and insulin resistance?

To fix insulin resistance in PCOS, you have to understand how it hijacks your reproductive hormones.

In a healthy metabolism, insulin unlocks your cells so they can absorb glucose for energy. In PCOS, chronic low-grade inflammation — often originating from belly fat or gut microbiome imbalances — interferes with insulin signaling in your peripheral tissues. Your muscle, fat, and liver cells resist the signal, so your pancreas expands its beta cells and pumps out massive amounts of insulin to force glucose into those tissues.

This compensatory high insulin — clinically called hyperinsulinemia, or high circulating insulin — acts as a massive amplifier to your reproductive disruption. It worsens hormone balance through two distinct mechanisms (Diamanti-Kandarakis & Dunaif 2012).

First, insulin directly overstimulates the testosterone-making layer of your ovary. The theca cells already respond to a brain hormone called luteinizing hormone (LH); insulin enhances that LH signal at the theca-cell level, telling the ovary to overproduce androgens like testosterone and androstenedione. The excess local testosterone disrupts normal follicle development, causing follicles to arrest before maturing. When follicles arrest, ovulation fails — the mechanistic link between insulin resistance and missed periods (Goodarzi et al. 2011).

Second, high insulin and the metabolic dysfunction that travels with it drastically reduce your liver's production of sex hormone-binding globulin (SHBG) — a protein in your blood that binds up loose testosterone, so when SHBG drops, more testosterone is free to drive symptoms. In a healthy state, SHBG keeps 98 to 99 percent of your testosterone bound and inactive; only 1 to 2 percent is unbound and biologically available. When insulin resistance and liver fat accumulation suppress SHBG, that small pool of free testosterone expands rapidly. Newer mechanistic work shows the SHBG drop is driven less by insulin directly than by liver fat and inflammatory cytokines from belly fat, which together shut down the liver gene that produces SHBG.

There is also a third reinforcing layer at the level of your brain. The part of your brain that paces hormone signals to your ovaries normally fires at a specific rhythm. In PMOS, that rhythm is abnormally rapid, pushing the brain to release excess LH while keeping FSH (the follicle-maturing signal) suppressed. Insulin signaling in those same brain cells worsens the rapid-pulse pattern, locking in the elevated LH-to-FSH ratio characteristic of the condition (McCartney & Campbell 2020).

The result is a tight, self-reinforcing loop: insulin resistance drives up free testosterone, free testosterone drives symptoms, the inflammatory load worsens the insulin resistance. This is why "just diet harder" fails for so many women — the loop has multiple entry points, and metabolic interventions, SHBG support, and inflammatory-load reduction all have to move together.

What are the signs and symptoms of insulin resistance in PCOS?

Because insulin resistance is a systemic metabolic issue, the signs show up across your body, not just in your cycle.

The PCOS belly pattern. Systemic insulin resistance is frequently rooted in visceral fat accumulation — fat stored around the abdominal organs rather than under the skin of your hips or thighs. Elevated insulin promotes this central storage pattern, and that fat is then metabolically active: it secretes inflammatory chemicals (TNF-alpha, IL-6, and related cytokines) that directly block insulin receptors on your muscle and liver, making the resistance worse. The midsection weight pattern feels stubborn precisely because the visceral fat is both symptom and driver.

Acanthosis nigricans. Severe insulin resistance often presents visibly as dark, velvety patches on the back of your neck, in your armpits, or in your groin. They happen when massive amounts of circulating insulin cross-react with growth-factor receptors on your skin cells, stimulating them to overgrow. When the underlying metabolic dysfunction is treated, the patches typically soften and lighten over months.

Androgenic skin and hair symptoms. Because high insulin drives up free testosterone, the classic signs of androgen excess are downstream of the loop: inflammatory acne along the jawline, chin, and chest (frequently flaring the week before your period as progesterone drops); hirsutism (unwanted facial or body hair growth, scored clinically using the Ferriman-Gallwey system) (Ferriman & Gallwey 1961); and diffuse scalp thinning driven by an enzyme that converts testosterone into its stronger form (DHT), which slowly shrinks the hair follicle.

Fatigue and sugar cravings. When your cells resist insulin, they are effectively starved for energy even when plenty of glucose is in your bloodstream. The energy deficit triggers intense carbohydrate cravings and profound post-meal fatigue — the afternoon crash most insulin-resistant women describe almost identically.

Irregular or absent cycles. Because excess testosterone arrests follicle development, ovulation fails to occur reliably. Cycles lengthen, become unpredictable, or stop. This is also what drives the high anti-Müllerian hormone (AMH — a hormone made by your follicles) seen on blood tests in PCOS: arrested follicles accumulate and each secretes AMH at elevated rates.

If most of these patterns are familiar, the next step is getting the right lab work to confirm what is actually driving them.

How do you know if you have insulin resistance?

Many women with PCOS are told they do not have insulin resistance because their fasting glucose or HbA1c came back normal. This is one of the most common diagnostic failures in PCOS care.

Fasting glucose and HbA1c only become abnormal when your pancreas is finally exhausted and can no longer produce enough insulin to overcome your cellular resistance. By the time your blood sugar rises into the prediabetes range (fasting glucose 100–125 mg/dL, or HbA1c 5.7–6.4 percent), you have likely been highly insulin resistant for years. Type 2 diabetes (fasting glucose ≥126 mg/dL, or HbA1c ≥6.5 percent) is the late-stage version of the same loop.

To identify insulin resistance years earlier, clinicians measure fasting insulin alongside fasting glucose to calculate your Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) — a blood test that measures how insulin-resistant you actually are. A HOMA-IR score above 2.0 to 2.5 indicates probable insulin resistance, even if your blood sugar is perfectly normal.

The labs worth asking for specifically:

• Fasting insulin — rarely run on a routine panel unless you ask. The single most useful early marker.
• Fasting glucose — paired with fasting insulin to calculate HOMA-IR.
• HOMA-IR — calculated from the above two.
• HbA1c — flags progression into prediabetes or diabetes range.
• Total and free testosterone — measured ideally via tandem mass spectrometry; direct free-testosterone tests are unreliable.
• SHBG — low SHBG with low-normal total testosterone often masks high free testosterone.
• AMH — the 2023 international PMOS guideline added AMH as an alternative to ultrasound for the polycystic-morphology criterion in adults (Teede et al. 2023). A serum AMH above roughly 35 pmol/L (5 ng/mL) is more sensitive than the older follicle-count threshold (Dewailly et al. 2011).
• Lipid panel — fasting triglycerides, HDL, LDL. Dyslipidemia frequently accompanies the insulin-resistant pattern.

If your clinician has only run fasting glucose and HbA1c, early insulin resistance can be invisible on paper for years.

How does insulin resistance differ across PCOS subtypes?

Among Functional Medicine and integrative-nutrition practitioners, a four-subtype framework is commonly used to categorize how PCOS presents: insulin-resistant, post-pill, inflammatory, and adrenal. These are not separate diseases — they are distinct physiological pathways, each requiring a different strategy. The peer-reviewed nosology underneath is the Rotterdam phenotype framework (phenotypes A through D), which describes the same clinical heterogeneity without explicitly identifying the underlying driver. In current PMOS literature, the four functional subtypes are described as a clinical-nutrition heuristic rather than a formally recognized diagnostic classification.

The insulin-resistant subtype accounts for roughly 70 percent of PCOS cases — the classic metabolic picture this article walks through, where hyperinsulinemia directly drives ovarian testosterone production and suppresses hepatic SHBG.

The adrenal subtype, roughly 10 percent of cases, looks visibly identical — same hirsutism, acne, hair thinning — but the driver is entirely different. It is characterized by an isolated elevation of DHEA-S (a hormone your adrenal glands make) alongside normal ovarian testosterone and normal fasting insulin. The adrenal pathway is governed by your brain's stress signal (ACTH), not by insulin or LH. Standard insulin-focused treatments do not move the adrenal driver, which is why women with this pattern often feel "the PMOS protocol is not working."

The inflammatory subtype describes women with androgen excess and ovulatory dysfunction but no primary insulin resistance. The driver is chronic systemic inflammation — often from gut permeability, autoimmune conditions like Hashimoto's thyroiditis, or chronic immune activation — which stimulates ovarian androgen synthesis through inflammatory pathways rather than insulin.

The post-pill subtype is a temporary, withdrawal-induced state. When a woman discontinues combined oral contraceptives — particularly those with anti-androgenic progestins like drospirenone or cyproterone acetate — she frequently experiences a temporary surge in androgen production as her body recalibrates. The presentation typically resolves spontaneously within three to six months.

Sub-typing is what makes any protocol work. If your bloodwork shows HOMA-IR above 2.5 and low SHBG, the protocol below applies. If your bloodwork shows normal fasting insulin with elevated DHEA-S, or normal insulin with high inflammatory markers, the same generic "low-carb diet plus metformin" plan will not move the needle.

How does insulin resistance drive other PCOS complications?

The chronic hyperinsulinemia and low-grade inflammation that define the insulin-resistant pattern drive significant long-term risks across the cardiovascular, hepatic, and respiratory systems.

Cardiometabolic risk and type 2 diabetes

Women with PCOS face substantially elevated cardiometabolic risk. A foundational meta-analysis showed roughly 2.5-fold higher odds of impaired glucose tolerance, 4.4-fold higher odds of type 2 diabetes, and nearly 3-fold higher odds of metabolic syndrome compared to controls (Moran et al. 2010). Dyslipidemia — elevated LDL, increased triglycerides, decreased HDL — is the most common metabolic abnormality, driven by both insulin resistance and the direct effect of excess testosterone on lipid metabolism (Randeva et al. 2012). The risk accumulates across decades; women who address the insulin loop in their twenties and thirties carry a fundamentally different long-term trajectory.

Nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) affects approximately 43 percent of PCOS patients — significantly higher than the general female population. Systemic insulin resistance promotes the creation of new fat inside the liver and increases the flow of free fatty acids from your belly fat to your liver. Excess testosterone independently suppresses the liver's ability to clear lipids from your bloodstream. The combined effect is that PCOS does not just cause simple fatty liver — it actively drives early progression toward liver inflammation and damage.

Obstructive sleep apnea

Obstructive sleep apnea (OSA) occurs at a 5- to 30-fold higher frequency in women with PCOS than in healthy controls, even after adjusting for body weight. The recurrent airway collapse causes intermittent drops in oxygen, which trigger oxidative stress and systemic inflammation. That inflammation feeds directly back into peripheral insulin resistance. Sleep apnea acts as an independent metabolic amplifier — accelerating progression from insulin resistance to impaired glucose tolerance to type 2 diabetes. If you snore, wake unrefreshed, or your partner has noticed breathing pauses, a sleep study is worth requesting.

Endometrial protection and chronic anovulation

When insulin resistance arrests ovulation, the post-ovulation progesterone surge that normally halts uterine lining growth and triggers a period also goes missing. Your body keeps producing estrogen, and excess androgens in your belly fat are converted into additional estrogen by the enzyme aromatase. The result is continuous, unopposed estrogen stimulation of your uterine lining, which can drive overgrowth (endometrial hyperplasia) and, over time, elevates the long-term risk of Type I endometrial cancer in women with chronically anovulatory PCOS (Barry et al. 2014). This is a major reason restoring regular ovulation — or providing cyclic progestin support when ovulation cannot be restored — matters beyond fertility.

What is the best diet for insulin-resistant PCOS?

Dietary intervention for insulin-resistant PCOS focuses on managing insulin secretion and improving peripheral insulin sensitivity. The 2018 international PMOS guideline establishes lifestyle modification as first-line, with 150–250 minutes per week of moderate exercise and an initial 5 percent body weight loss target (Teede et al. 2018). The 5 percent number matters because it is the threshold where insulin sensitivity meaningfully improves and ovulatory function frequently restores — not a cosmetic target.

Across evidence-based dietary patterns — Mediterranean, DASH, pulse-based, monitored lower-carb — the common mechanism is reduction of glycemic load. Glycemic load is more functional than glycemic index because it accounts for both how fast a food raises blood sugar and how many carbohydrate grams are in a serving.

The plate-method framework for insulin-resistant PCOS:

1. Half the plate: non-starchy vegetables. Leafy greens, broccoli, cauliflower, zucchini, peppers, cucumber. Fiber slows gastric emptying and blunts glucose absorption, producing a smaller insulin response. The single highest-leverage shift in the day's meals. 2. One quarter: high-quality protein. Fish, eggs, chicken, lean beef, tofu, tempeh. Protein is satiating and provides amino acids without triggering the kind of insulin surge that refined carbohydrates produce. 3. One quarter: low-glycemic, fiber-rich carbohydrates. A 16-week randomized trial demonstrated that a low-glycemic pulse-based diet (lentils, beans, chickpeas) produces greater reductions in insulin AUC and better lipid profiles in PCOS women than a generic therapeutic lifestyle diet (Kazemi et al. 2018). Quinoa, sweet potato, and steel-cut oats fit the same low-GL principle. 4. Add healthy fats. Fats do not trigger an insulin response. Long-chain omega-3 fatty acids from wild-caught fish (or high-quality fish oil) reduce systemic inflammation and bioavailable testosterone in PCOS women (Phelan et al. 2011) and, in a separate trial, significantly reduce hepatic fat content — addressing the NAFLD risk discussed above (Cussons et al. 2009).

There is also a meaningful conversation about dairy. Dairy milk contains a growth factor (IGF-1) that gets amplified when insulin is high, plus precursors to DHT, the stronger form of testosterone that drives acne. For women whose acne is a dominant symptom, trialing dairy elimination is worth considering (Melnik 2009). The broader pattern of foods that feed the insulin loop is covered in our guide to 11 foods to avoid if you have PCOS.

The principle: stable blood sugar across the day means a quieter ovarian-testosterone signal, lower visceral fat deposition, and more SHBG in your bloodstream binding loose testosterone. The plate is the lever.

What are the best supplements for insulin-resistant PCOS?

The targeted supplement set most consistent with the peer-reviewed evidence for the insulin-resistant pattern is covered in depth in our review of PCOS weight loss supplements and vitamins; the highest-leverage three for insulin resistance specifically are below.

Inositol in the 40:1 myo-to-D-chiro ratio

Inositol functions as a secondary messenger inside your cells — the molecule that translates the insulin signal at the cell surface into the action of pulling glucose inside. Two forms matter: myo-inositol (MI) and D-chiro-inositol (DCI). MI is critical for follicle maturation and the FSH-to-LH balance; DCI is more involved in insulin signaling. The body converts MI to DCI as needed.

In hyperinsulinemic states like insulin-resistant PCOS, this conversion is abnormally accelerated, depleting MI inside the ovary and producing an excess of DCI exactly where it should not be. The depleted MI impairs egg quality and disrupts ovulation. Healthy women maintain a plasma ratio of 40:1 (MI to DCI) — the ratio shown clinically to restore metabolic and hormonal parameters faster than myo-inositol alone, improving insulin sensitivity and reducing hyperandrogenism without impairing follicle development (Nordio & Proietti 2012). Across the broader literature, myo-inositol supplementation in PCOS women consistently improves ovulatory function and reduces hyperandrogenism markers (Unfer et al. 2012). The deeper breakdown of how the 40:1 ratio works clinically is in our guide to Ovasitol.

Vitamin D

Vitamin D functions systemically as a prohormone, regulating thousands of genes including those involved in cellular signaling and immune function. Because it is fat-soluble, vitamin D is actively sequestered by body fat — so the expanded visceral adiposity frequently seen in insulin-resistant PCOS acts as a sink, lowering circulating bioavailable vitamin D and driving high rates of clinical deficiency.

Correcting that deficiency is metabolically protective. Across 11 randomized trials in 601 PCOS women, vitamin D co-supplementation significantly reduced fasting glucose and improved HOMA-IR scores, with doses below 4000 IU per day showing the strongest insulin-sensitivity effect (Łagowska et al. 2018). Vitamin D will not directly induce weight loss, but it removes a compounding variable from systemic insulin resistance. Get your serum 25-hydroxyvitamin D checked before supplementing — dosing should match deficiency severity.

Berberine

Berberine is a plant alkaloid that acts on similar pathways as metformin — activating cellular energy sensors that improve insulin sensitivity. A trial comparing berberine head-to-head against metformin in PCOS women showed comparable effects on insulin sensitivity and hyperandrogenism, with greater improvements in body composition and lipid profiles (Wei et al. 2012). It is most useful for women who cannot tolerate metformin's gastrointestinal side effects.

Two caveats. Berberine inhibits an enzyme (CYP3A4) that clears many medications from your body, so it interacts with a long list of prescription drugs, including some hormonal contraceptives — run it past your prescriber if you are on other medications. Supplement quality also varies enormously; published testing has found less than half of commercial berberine products contain the labeled dose.

What medical treatments help control insulin resistance in PCOS?

When dietary and supplemental interventions are not enough — or when the underlying insulin resistance is severe — pharmacological treatment is appropriate.

Metformin

Metformin is the most frequently prescribed off-label medication for insulin resistance in PCOS, particularly in women with a body mass index above 25. At the cellular level, metformin activates an enzyme called AMPK, which decreases glucose production in your liver and forces your skeletal muscles to take up glucose from your bloodstream independent of insulin. By lowering your circulating insulin levels, metformin also exerts an indirect anti-androgenic effect — reducing testosterone levels by as much as 50 percent in insulin-resistant women and helping acanthosis nigricans patches gradually soften as the systemic metabolic driver resolves.

Two practical notes. Metformin commonly causes gastrointestinal side effects (nausea, diarrhea, cramps), so dosing must be ramped gradually — typically starting at 500 mg per day with food and increasing to 1000 to 1700 mg per day. Long-term use depletes vitamin B12 by reducing its gut absorption, requiring monitoring. Metformin is largely ineffective for hirsutism; severe hair growth requires targeted antiandrogen therapy or direct removal.

GLP-1 receptor agonists

For women with insulin-resistant PCOS and concurrent metabolic syndrome or severe obesity who do not achieve adequate metabolic control through lifestyle and metformin, glucagon-like peptide-1 (GLP-1) receptor agonists — including semaglutide and tirzepatide — are increasingly used. They enhance glucose-dependent insulin secretion, slow gastric emptying, and act on appetite centers in the brain to promote satiety. The substantial weight loss they produce reduces visceral fat burden, lowers inflammatory output, and improves peripheral insulin sensitivity. They are an escalation, not a starting point.

Combined oral contraceptives

Combined oral contraceptives (COCs) are first-line for regulating cycles and managing hyperandrogenic skin and hair symptoms. The estrogen component stimulates the liver to produce more SHBG — increasing circulating SHBG two- to four-fold and decreasing free testosterone by 40 to 80 percent. The progestin component prevents endometrial overgrowth, important because chronic anovulation otherwise drives the long-term endometrial cancer risk.

The choice of progestin matters significantly. First-generation progestins (norethindrone, levonorgestrel) can worsen acne and hirsutism by displacing testosterone from SHBG. Third- and fourth-generation progestins (desogestrel, norgestimate, drospirenone) and the anti-androgenic cyproterone acetate are preferred. Worth asking your prescriber explicitly: which progestin is in this pill, and is it appropriate for my androgen pattern?

Letrozole for fertility

For women with insulin-resistant PCOS trying to conceive, the first-line treatment to induce ovulation is letrozole — an aromatase inhibitor that temporarily blocks the conversion of androgens to estrogen, prompting more FSH release and driving follicle maturation. A multicenter randomized trial in 750 PCOS women showed cumulative live birth rates of 27.5 percent versus 19.1 percent for clomiphene (Legro et al. 2014), and a Cochrane meta-analysis across 42 trials confirmed letrozole's superiority without increased ovarian hyperstimulation risk (Franik et al. 2018). Treating the underlying insulin resistance alongside ovulation induction produces more robust outcomes.

How does insulin resistance affect pregnancy and gestational diabetes?

If you have insulin-resistant PCOS and achieve pregnancy, clinical management must immediately pivot to monitoring for gestational diabetes mellitus (GDM). PCOS is a classical, independent risk factor for GDM.

During a healthy pregnancy, placental hormones induce a state of physiological insulin resistance in the second and third trimesters to ensure a steady glucose supply for the fetus. In women with PCOS, your preexisting peripheral insulin resistance compounds that new metabolic load. When your pancreas fails to scale insulin output to meet the increased demand, maternal high blood sugar results.

Clinical guidelines recommend early GDM screening in PCOS patients, often at the first prenatal visit rather than waiting for the standard 24-to-28-week oral glucose tolerance test. Management relies heavily on low-glycemic-load diets and moderate-intensity resistance training. Metformin is sometimes continued during pregnancy under clinical supervision; observational data suggests it can decrease GDM incidence, reduce excessive maternal weight gain, and lower supplemental insulin requirements, though long-term offspring data is still accumulating. If lifestyle and oral interventions cannot maintain glycemic targets, fast-acting insulin therapy is introduced.

Postpartum follow-up matters: because 50 to 60 percent of women who develop GDM go on to develop type 2 diabetes within years to decades, a repeat oral glucose tolerance test six to twelve weeks after delivery — and ongoing metabolic monitoring beyond that — is part of standard PCOS-pregnancy care.

Putting it together

Insulin-resistant PCOS is not a willpower problem. It is a self-reinforcing biological loop with multiple entry points — pancreas, liver, ovary, brain, gut, and belly fat all feeding into each other. Reversing it means pulling levers across that loop in coordination: glycemic load on the plate, the right targeted supplements, sleep that lets your stress axis recalibrate, vitamin D corrected, and — when warranted — pharmacological support to lower the insulin signal directly.

The lab work is the diagnostic gate. If your HOMA-IR is above 2.5 and your SHBG is low, the insulin-resistant pattern is what you are working with, and the protocol above applies. If your bloodwork tells a different story — normal insulin with elevated DHEA-S, or normal insulin with high inflammatory markers — the work shifts toward the adrenal, inflammatory, or post-pill presentations instead.

PCOS — under whatever name it carries in the next decade of medical literature, whether PCOS or PMOS — is heterogeneous by definition. Treating yours starts with knowing which version you have, then working the actual loop.